NCT01398449Unknown3 期
Is Elective Nodal Irradiation (ENI) Necessary For Patients With Thoracic Esophageal Squamous Cell Carcinoma Who Undergo Esophagectomy And With Pathological Stage Of T1-2,N+,M0 -- A Randomized Phase Ⅲ Trial
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 874
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
Is elective nodal irradiation (ENI) necessary for patients with thoracic esophageal cancer after esophagectomy and with pathological stage of T1-2,N+,M0?
详细描述
Patient Population:
Thoracic esophageal squamous cell carcinoma after esophagectomy with at least 15 lymph nodes removed for adequate nodal staging.
R0 resection; T1-2, N+, M0.
Scheme:
After esophagectomy, patients are firstly stratified by numbers of lymph node metastasis (<3 or >=3). Then patients are randomized to 2 arms:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 and ≤70
- •ECOG performance status 0-1
- •Weight is not less than 90% of it before operation
- •Registration within 8 weeks after esophagectomy
- •Histologically proven primary thoracic esophageal squamous cell carcinoma
- •R0 resection and number of lymph nodes dissected ≥15 after esophagectomy
- •Stage T1-2N1-3M0 based pathological diagnosis
- •Chest and abdominal contrast enhanced CT within 6 weeks prior to registration(PET/CT scan is selective)
- •Without supraclavicular nodes and abdominal regions nodes existed after surgery
- •Without neo-adjuvant chemotherapy and radiotherapy
- •WBC≥ 4.0X109/L ,Absolute neutrophil count (ANC) ≥ 2.0X109/L
- •Platelets ≥ 100X109/L
- •Hemoglobin ≥ 90g/L(without blood transfusion)
- •AST (SGOT)/ALT (SGPT) ≤ 2.5 x upper limit of normal, Bilirubin ≤ 1.5 x upper limit of normal
- •Creatinine ≤ 1.5 x upper limit of normal
- •Sign study-specific informed consent prior to study entry
排除标准
- •Multiple primary esophageal tumors
- •Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible).
- •Severe, active comorbidity, defined as follows:
- •3.1 Unstable angina and/or congestive heart failure requiring hospitalization within the last 3 months 3.2 Transmural myocardial infarction within the last 6 months 3.3 Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration 3.4 Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration 3.5 Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
- •Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.
- •Prior systemic chemotherapy, prior radiation therapy or prior target drug therapy
结局指标
主要结局
Overall survival
To evaluate elective nodal irradiation (ENI) is better for the overall survival of patients with thoracic esophageal cancer after esophagectomy who with pathological stage of T1-2, N positive, M0
次要结局
- Locoregional control rate
- Safety and Tolerability (incidence rate of adverse events)
- Failure pattern
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Adjuvant Radiotherapy for pT1b Esophageal Cancer After Submucosal Endoscopic ResectionEsophageal CancerNCT05499195Chinese Academy of Medical Sciences159
已完成
2 期
Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal CarcinomaEsophageal CarcinomaNCT00176800University of Michigan Rogel Cancer Center69
进行中（未招募）
2 期
Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal CancerEsophagus CancerNeoadjuvant TherapyNCT04776590Wuhan Union Hospital, China30
已完成
2 期
eoadjuvant chemoradiotherapy followed by esophagectomy for REG I positive T4, N4 or many thoracic esophageal cancerthoracic esophageal cancerJPRN-UMIN000001626The Cancer Board of Esophageal Cancer in Akita University Hospital30
进行中（未招募）
1 期
Electric pulse treatment in esophageal cancerMedDRA version: 19.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 100000004864Esophageal cancerEUCTR2015-005246-59-DKMichael Patrick Achiam